Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals has demonstrated robust revenue growth, particularly with Dupixent, which achieved a 32% year-over-year increase in net product revenues to $4.94 billion in the fourth quarter of 2025, driven by expansion into established indications and successful launches in new therapeutic areas. Meanwhile, Eylea HD is projected to see substantial sales growth, with US consensus estimates rising from approximately $1.6 billion in 2025 to $2.8 billion by 2028, reflecting its increasing share in the anti-VEGF market. The company's ongoing advancements in its pipeline, highlighted by collaborations on monoclonal and bispecific antibodies as well as early-stage partnerships for new technologies like RNAi and CRISPR-based gene editing, position Regeneron favorably for future growth.

Regeneron Pharmaceuticals is experiencing a significant decline in sales, particularly with a 52% year-over-year decrease in Eylea sales in Q4 2025, largely attributed to the shift to Eylea HD and competition from the biosimilar Pavblu. The company anticipates slower revenue growth as Dupixent is projected to reach its peak around 2031, with expectations of a decline thereafter due to potential impacts from the Inflation Reduction Act and emerging competition. Additionally, Regeneron has adjusted its fiscal year 2026 estimated sales for Eylea down from $2.0 billion to $1.1 billion, signaling ongoing pressures on its key revenue-generating products.